SEAL

SOLOTECH MARKS 45TH ANNIVERSARY

Retrieved on: 
Thursday, April 21, 2022
Online, CBCI, CEO, Technology, Government, Ascot Racecourse, Culture, The Rolling Stones, Capital Sound, Waveform, Transport, Future, Music, System integration, Education, Caesars Palace, Growth, Ubisoft, Heart, United Kingdom, Solution, Lighting, Multimedia, Industry, Sport, Montreal International Jazz Festival, SEAL, Video game, Sound, Online and offline, Bridgestone Arena

Now recognized worldwide as a partner of choice, Solotech has proven that it can meet all audiovisual and entertainment technology needs.

Key Points: 
  • Now recognized worldwide as a partner of choice, Solotech has proven that it can meet all audiovisual and entertainment technology needs.
  • Founded in 1977 by Denis Lefranois and Andr Riendeau, Solotech was initially dedicated solely to audio.
  • Solotech was agile with its growth into new, state-of-the-art facilities to better manage its operations and immense equipment inventory.
  • Martin Tremblay, President and CEO of Solotech: "I am thrilled by this anniversary, its shows how seasoned Solotech is in the industry.

SOLOTECH MARKS 45TH ANNIVERSARY

Retrieved on: 
Thursday, April 21, 2022
Online, CBCI, CEO, Technology, Government, Ascot Racecourse, Culture, The Rolling Stones, Capital Sound, Waveform, Transport, Future, Music, System integration, Education, Caesars Palace, Growth, Ubisoft, Heart, United Kingdom, Solution, Lighting, Industry, Sport, Montreal International Jazz Festival, SEAL, Video game, Sound, Online and offline, Bridgestone Arena

MONTREAL, April 21, 2022 /CNW Telbec/ - Solotech is proud to blow out 45 candles this year!

Key Points: 
  • MONTREAL, April 21, 2022 /CNW Telbec/ - Solotech is proud to blow out 45 candles this year!
  • Now recognized worldwide as a partner of choice, Solotech has proven that it can meet all audiovisual and entertainment technology needs.
  • Founded in 1977 by Denis Lefranois and Andr Riendeau, Solotech was initially dedicated solely to audio.
  • Martin Tremblay, President and CEO of Solotech: "I am thrilled by this anniversary, its shows how seasoned Solotech is in the industry.

Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board

Retrieved on: 
Wednesday, April 20, 2022
Odyssey, News, Concussion, Navy, Special Operations Command, Amnesia, Squadron, Clinical trial, USSOCOM, Commander, Pathology, Twitter, Special mission unit, NATO, Anxiety, CA, Traffic barrier, Oxidative stress, Private Securities Litigation Reform Act, SEAL Team, Brain, GLOBE, Inflammation, Veteran, United States Special Operations Command, Employment, Hispanics in the United States Naval Academy, Company, OTC Markets Group, Policy, Neurosteroid, Assistant, NSW, Commander, Naval Forces Vietnam, Joint Special Operations University, SEAL, Pharmaceutical industry, Medical imaging

Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Companys prestigious Military Advisory Board.

Key Points: 
  • Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Companys prestigious Military Advisory Board.
  • Vice Admiral (r) Szymanski has led and served in many Navy and Joint Special Operations assignments as a Navy Special Warfare Officer (SEAL) for over 36 years.
  • He most recently served as the Deputy Commander for United States Special Operations Command (USSOCOM) after serving as the Commander of Naval Special Warfare (NSW).
  • Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions.

Ernesto Arellano Launches All Protection Solutions Corp

Retrieved on: 
Wednesday, April 6, 2022
Riverside Park Management, SEAL, GPS, COVID-19, APS, Special Event Line (San Diego Trolley), CEO, Incident, Industry, Technology, Founder CEO, Internet service provider, News

SEAL BEACH, Calif., April 6, 2022 /PRNewswire/ -- All Protection Solutions Corp. (APS), a security services company serving Riverside, Orange Counties and surrounding areas in Southern California, expands with an intensified rebranding launch. From implementing new security technology, APS-Trax, real-time reporting for clients, establishing the highest standards in security guard training, and providing new, on-site security vehicles, APS is setting new security standards in their Southern California market.

Key Points: 
  • SEAL BEACH, Calif., April 6, 2022 /PRNewswire/ --All Protection Solutions Corp. (APS), a security services company serving Riverside, Orange Counties and surrounding areas in Southern California, expands with an intensified rebranding launch.
  • With over 23 years of industry experience, Ernesto Arellano, Founder & CEO of APS, is determined to lead his company with great advancements.
  • Arellano says, "We used the Covid Pandemic as a time to assess the industry and evaluate the security needs of Southern California."
  • With rigorous and ongoing premier education, the APS Training includes:
    All Protection Solution Corp (APS) is a security services company serving Riverside and Orange Counties and other areas in Southern California.

Murphy Oil Corporation Announces Results of Cutthroat-1 Exploration Well Offshore Brazil

Retrieved on: 
Monday, March 28, 2022
Oil, Gas, Energy, Private Securities Litigation Reform Act, SEAL, Forward-looking statement, NYSE, China National Offshore Oil Corporation, Failure, Thought, Murphy Oil, Hydrocarbon, Industry, U.S. Securities and Exchange Commission, COVID-19, Sumathi Best Television Current Reporting Award, MUR, News, Annual report, ExxonMobil, Water, Partnership, Petroleum, Oil

Murphy Oil Corporation (NYSE: MUR) today announced that drilling has concluded at the Cutthroat-1 exploration well in block SEAL-M-428 in the Sergipe-Alagoas Basin offshore Brazil.

Key Points: 
  • Murphy Oil Corporation (NYSE: MUR) today announced that drilling has concluded at the Cutthroat-1 exploration well in block SEAL-M-428 in the Sergipe-Alagoas Basin offshore Brazil.
  • Cutthroat-1 is located nearly 90 kilometers offshore Brazil and was drilled in 3,094 meters of water by the Seadrill West Saturn drillship.
  • Enauta Energia S.A. holds 30% working interest and Murphy Oil Corporation holds 20% working interest in the partnership.
  • As an independent oil and natural gas exploration and production company, Murphy Oil Corporation believes in providing energy that empowers people by doing right always, staying with it and thinking beyond possible.

Vallon Pharmaceuticals Announces Topline Results of its Pivotal SEAL Study for Lead Program, ADAIR, for the Treatment of ADHD

Retrieved on: 
Monday, March 21, 2022
Safety, SEAL, NASDAQ, CNS, Sexual abuse, PD, History, Food, Dextroamphetamine, Attention deficit hyperactivity disorder, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, CRO, ADHD, Central nervous system disease, FDA, Medical imaging, Pharmaceutical industry, Pharmacokinetics

Philadelphia, PA, March 21, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today announced topline results from its pivotal SEAL study evaluating ADAIR, a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine for the treatment of attention deficit hyperactivity disorder (ADHD).

Key Points: 
  • While we are disappointed by the primary endpoint results, many of the topline findings are encouraging and provide valuable insight, commented David Baker, President & Chief Executive Officer of Vallon.
  • The SEAL study enrolled 55 subjects, of whom 53 completed the study and 52 were included in the final analysis.
  • The study involved a four-way crossover design to evaluate professionally manipulated, intranasal ADAIR 30 mg, crushed intranasal dextroamphetamine, ADAIR 30 mg taken orally, and placebo.
  • Beyond these topline results, additional calculation and analysis of other endpoints with our CRO partner will begin shortly including the pharmacokinetic results and results of other exploratory endpoints.

Seapeak LLC Declares Distributions on Series A and B Preferred Units

Retrieved on: 
Thursday, March 17, 2022
GLOBE, NYSE, LPG, Ownership, Form 1099, SEAL, Natural gas, LNG

HAMILTON, Bermuda, March 17, 2022 (GLOBE NEWSWIRE) -- Seapeak LLC has declared cash distributions of $0.5625 per unit on the Companys Series A preferred units (NYSE:SEAL PR A) and $0.5313 per unit on the Companys Series B preferred units (NYSE:SEAL PR B) for the period from January 1, 2022 to March 31, 2022.

Key Points: 
  • HAMILTON, Bermuda, March 17, 2022 (GLOBE NEWSWIRE) -- Seapeak LLC has declared cash distributions of $0.5625 per unit on the Companys Series A preferred units (NYSE:SEAL PR A) and $0.5313 per unit on the Companys Series B preferred units (NYSE:SEAL PR B) for the period from January 1, 2022 to March 31, 2022.
  • The cash distributions are payable on April 14, 2022 to all unitholders of record as at March 31, 2022.
  • Seapeaks preferred unit distributions are reported on Form 1099 for United States tax purposes.
  • In addition, Seapeak owns a 30 percent interest in an LNG regasification terminal.

Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing

Retrieved on: 
Friday, March 11, 2022
Cystic fibrosis, Safety, Biomarker, SEAL, CHF, USD, University, MAD, Company, Marketing, FDA, Mark (given name), EGM, Annual report, FOR, CF, Treasury, Degenerative disease, NDA, University of Basel, Convertible, Rutgers University, Greater, Leadership, NOT, Prednisone, Patient, Growth, Therapy, Vamorolone, Stock dilution, LR, File, Security (finance), Cryptocurrency, Pharmaceutical industry, DMD

53 LR

Key Points: 
  • 53 LR
    Cash and cash equivalents at February 28, 2022 of CHF18 million
    Issuance of 3,100,000 treasury shares from authorized capital on March10, 2022
    Planned additional issuance of 15,500,000 treasury shares in ordinary capital increase on March 14, 2022
    Pratteln, Switzerland, March 11, 2022 Santhera Pharmaceuticals (SIX: SANN) announces preliminary 2021 financial results and operational progress made.
  • With regard to business development, we closed two agreements, one of which already resulted in cash receipts in January 2022.
  • The share capital increase, approved by Santheras shareholders at the last EGM in December 2021, provides Santhera with additional financing flexibility to be able to raise funds.
  • Santhera continues to evaluate various non-dilutive and dilutive financing alternatives, using existing share capital authorizations and treasury shares, which may include existing shareholders subscription rights, depending on market conditions.

Symbiont Announces Expansion of Executive Leadership Team Naming New Chief Marketing Officer & Chief People Officer

Retrieved on: 
Thursday, March 10, 2022
People, Organizational culture, State Street, Nasdaq, Industry, Life, SEAL, Marine Corps Systems Command, Museum of American Finance, Twitter, Data, Smith, Workforce, Assembly, Director, SEAL Team, Culture, Entrepreneurship, Central Waqf Council, Board, Communications officer, Edelman, Privacy, Iraqi Ground Forces Command, Central Command, Child, Acceleration, Solution, Technology, United States Central Command, Social responsibility, CA, CMO, United States Navy SEALs, Museum, Association, History, CEO, McLennan, LinkedIn, Management, Symbiosis

Silvia Davi was namedSymbiont's Chief Marketing and Communications Officer and Tom DeJarnette was named Chief People Officer.

Key Points: 
  • Silvia Davi was namedSymbiont's Chief Marketing and Communications Officer and Tom DeJarnette was named Chief People Officer.
  • As Chief Marketing and Corporate Communications Officer, Silvia Davi is overseeing all aspects of global marketing, brand, corporate communications, public affairs, digital communications, investor relations and social responsibility.
  • Mark Smith, CEO of Symbiont commented, "I am delighted to welcome two exceptional professionals like Silvia and Tom to our leadership team.
  • The other critical milestone in 2021 was our organizational evolution and as a result the expansion of our executive team."

Santhera Signs Gene Therapy Agreement with SEAL Therapeutics

Retrieved on: 
Monday, February 28, 2022
Rutgers University, State university system, University, Biozentrum University of Basel, Therapy, Company, McKee, LHON, LAMA2, Cystic fibrosis, US, SEAL, Congenital muscular dystrophy, Leber's hereditary optic neuropathy, Vamorolone, Patient, Technology, DMD, MD, Research, Communication, Muscle weakness, Pharmaceutical industry

Pratteln, Switzerland, February 28, 2022 Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular dystrophy.

Key Points: 
  • Pratteln, Switzerland, February 28, 2022 Santhera Pharmaceuticals (SIX: SANN) announces the signing of an agreement with SEAL Therapeutics for a gene therapy approach targeting congenital muscular dystrophy.
  • Santhera has entered into an agreement with SEAL Therapeutics, a spin-off company from the Biozentrum of the University of Basel, which will further develop a gene therapy approach intended for the treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2MD).
  • SEAL Therapeutics will advance the gene therapy technology building on existing research progress from the Biozentrum Basel and Rutgers, both previously partially funded by Innosuisse and/or Santhera.
  • SEAL Therapeutics is well positioned to build on this groundbreaking research and attract a qualified pharmaceutical partner in the gene therapy area.